Targeted Chemoprevention for Melanoma

黑色素瘤的靶向化学预防

• 批准号: 8403919
• 负责人: Gavin P. Robertson
• 金额: $ 38.26万
• 依托单位: PENNSYLVANIA STATE UNIV HERSHEY MED CTR
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-03-12 至 2014-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8403919
• 关键词: Achievement; Animal Disease Models; Animal Model; Animals; Antibodies; Attention; Cell Survival; Cells; Chemoprevention; Chemopreventive Agent; Clinical; Cutaneous Melanoma; Development; Disease; Disease Progression; Drug Formulations; Excision; Gene Combinations; Gene Targeting; Goals; Health; Home environment; Human; Incidence; Interdisciplinary Study; Lead; Lesion; Liposomes; Luciferases; Lymphatic; Lymphatic System; Malignant Neoplasms; Mediating; Melanoma Cell; Metastatic Melanoma; Modeling; Monitor; Movement; Mus; Mutate; Operative Surgical Procedures; PTEN gene; Pathway interactions; Patients; Penetration; Phosphotransferases; Physiological; Premalignant; Primary Lesion; Primary Neoplasm; Proteins; Research; Sentinel Lymph Node Biopsy; Signal Transduction; Skin; Skin Cancer; Small Interfering RNA; Staging; Techniques; Technology; Testing; Time; Transgenic Animals; Transgenic Mice; Transgenic Model; Transgenic Organisms; Translations; Ultrasonography; Work; base; cancer cell; clinical application; clinically significant; design; innovation; interest; killings; lymph nodes; melanoma; migration; mortality; mutant; nanoliposome; nanoscale; novel; novel strategies; prevent; public health relevance; reconstruction; tumor

DESCRIPTION (provided by applicant): Malignant melanoma is the most deadly of all skin cancers. Despite its lethality, no targeted topical chemopreventive agents exist to inhibit this cancer in its earliest forms or when cells are present in the lymphatic system in the proximity of the early primary lesion. Among possible chemopreventive targets is Akt3 whose activity increases in ~70% of tumors to promote melanoma development. Targeting early melanocytic lesion cells using siRNA-based agents to inhibit Akt3 and other key kinases could be important for targeted melanoma chemoprevention, but delivery of siRNA remains a challenge. Currently, no technology or approach utilizes siRNA as a chemopreventive agent to inhibit early melanoma development. This application focuses on melanoma chemoprevention by targeting early melanocytic lesions using siRNA-based agents to inhibit Akt3 and mutant V600EB-Raf, GSK31 or Wee1 kinases, which are shown to synergistically inhibit melanocytic lesion cells. Thus, the central hypothesis for the proposed research is that siRNA targeting Akt3 and mutant V600EB-Raf, GSK31 or Wee1 kinases can be delivered via novel ultrasound-nanoliposomal technology into skin containing early melanocytic lesions to prevent melanoma development and invasion of these cells into or through the lymphatic system. The rationale is that siRNA targeting these genes would serve as pathway specific targeted chemopreventive agents to prevent melanoma development. We formulated this hypothesis based on proof-of-principal preliminary discoveries identifying kinases to target that can synergise with Akt3 inhibition. Furthermore, we show that siRNA against Akt3 and V600EB-Raf can be loaded into nanoliposomes and placed on skin containing melanocytic lesions following ultrasound treatment, effectively inhibiting melanoma cell survival, and if delivered together it can cooperatively prevent disease development. Thus, the objectives of this application are to first, evaluate the chemopreventive efficacy of novel nanoliposomes containing siRNA-targeting Akt3 and mutant V600EB-Raf, GSK31 or Wee1 kinases in a transgenic animal model of the disease in which both Akt3 and V600EB-Raf are deregulated to promote spontaneous melanocytic lesion development. This will be accomplished by loading siRNA targeting Akt3 and V600EB-Raf, GSK31 or Wee1 into antibody-targeted nanoliposomes and following ultrasound treatment, effectively deliver agents into spontaneously developing early melanocytic lesions in skin of animals. Second, we will determine whether these agents can prevent or decrease lymph node invasion by early melanocytic cells to decreased disease development and aid survival. This will be accomplished by treating mice with nanoliposomal siRNA prior to or following invasion of the lymph node basin by melanocytic lesion cells to establish whether it will prevent disease progression. Delivery of siRNA against key kinases using an antibody-targeted nanoliposomal formulation following ultrasound-mediated skin permeabalization is a novel approach critically needed for more effective chemoprevention of melanoma and inhibition of its spread into and through the lymphatic system.

描述（由申请人提供）：恶性黑色素瘤是所有皮肤癌中最致命的。尽管它的致命性，没有靶向的局部化学预防剂存在，以抑制这种癌症在其最早的形式或当细胞存在于淋巴系统中的早期原发性病变附近。可能的化学预防靶点之一是Akt 3，其活性在约70%的肿瘤中增加，以促进黑色素瘤的发展。使用基于siRNA的药物靶向早期黑色素细胞病变细胞以抑制Akt 3和其他关键激酶对于靶向黑色素瘤化学预防可能是重要的，但siRNA的递送仍然是一个挑战。目前，没有技术或方法利用siRNA作为化学预防剂来抑制早期黑色素瘤发展。本申请集中于通过使用基于siRNA的试剂靶向早期黑素细胞病变以抑制Akt 3和突变V600 EB-Raf、GSK 31或Wee 1激酶（其显示协同抑制黑素细胞病变细胞）的黑色素瘤化学预防。因此，拟议研究的中心假设是，靶向Akt 3和突变V600 EB-Raf，GSK 31或Wee 1激酶的siRNA可以通过新型超声纳米脂质体技术递送到含有早期黑色素细胞病变的皮肤中，以防止黑色素瘤的发展和这些细胞侵入或通过淋巴系统。基本原理是，靶向这些基因的siRNA将作为途径特异性靶向化学预防剂，以防止黑色素瘤的发展。我们基于鉴定可与Akt 3抑制协同作用的靶向激酶的主要证据初步发现制定了这一假设。此外，我们表明，针对Akt 3和V600 EB-Raf的siRNA可以加载到纳米脂质体中，并在超声治疗后放置在含有黑色素细胞病变的皮肤上，有效抑制黑色素瘤细胞存活，如果一起递送，则可以协同预防疾病发展。因此，本申请的目的是首先在该疾病的转基因动物模型中评价含有靶向siRNA的Akt 3和突变型V600 EB-Raf、GSK 31或Wee 1激酶的新型纳米脂质体的化学预防功效，其中Akt 3和V600 EB-Raf两者都被去调节以促进自发性黑素细胞病变发展。这将通过将靶向Akt 3和V600 EB-Raf、GSK 31或Wee 1的siRNA加载到抗体靶向纳米脂质体中并在超声处理后有效地将药剂递送到动物皮肤中自发发展的早期黑素细胞病变中来实现。其次，我们将确定这些药物是否可以预防或减少早期黑色素细胞的淋巴结侵袭，以减少疾病的发展和帮助生存。这将通过在黑素细胞病变细胞侵入淋巴结盆之前或之后用纳米脂质体siRNA治疗小鼠来实现，以确定其是否会阻止疾病进展。在超声介导的皮肤透化后使用抗体靶向纳米脂质体制剂递送针对关键激酶的siRNA是更有效地化学预防黑色素瘤和抑制其扩散到淋巴系统中和通过淋巴系统的新方法。